People with cardiovascular disease (i.e. affecting the heart and blood vessels) who use low-dose colchicine for at least six months will reduce their risk of myocardial infarction (heart attack) and ...

Depending on one’s perspective, the anti-inflammatory colchicine is either an unsung and underprescribed drug for patients with cardiovascular disease, or it’s an agent with limited clinical benefit ...

WASHINGTON, DC – OCTOBER 29, 2024 – The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce ...

Please provide your email address to receive an email when new articles are posted on . In patients referred for PCI after acute heart attack, colchicine did not improve heart-related outcomes vs.

Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, ...

Clinically important Afib occurred in 6.4% of colchicine-treated patients and 7.5% of placebo recipients (HR 0.85, 95% CI 0.65-1.10, P=0.22), David Conen, MD, of the Population Health Research ...